LENZ Therapeutics Launches VIZZ™ in the U.S. for the Treatment of Presbyopia

LENZ治疗公司在美国推出VIZZ™，用于治疗老花眼。

October 01, 2025

2025年10月01日

LENZ Therapeutics has announced that VIZZ™ (aceclidine ophthalmic solution, 1.44%), the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now commercially available in the United States. Product sampling to eye care professionals has begun, with broader consumer access expected by mid-Q4 2025..

LENZ Therapeutics 宣布，首款也是唯一获得 FDA 批准的基于乙酰氯化物的滴眼液 VIZZ™（乙酰氯化物眼用溶液，1.44%）现已在美国上市。目前已开始向眼科保健专业人士提供产品样品，预计到 2025 年第四季度中期消费者将获得更广泛的使用渠道。

U.S. Commercial Launch Underway

美国商业发射正在进行中

The launch of VIZZ marks a significant milestone in presbyopia care. LENZ has initiated nationwide sample distribution to optometrists and ophthalmologists, allowing professionals to provide early access to patients.

VIZZ的推出标志着老花眼护理的一个重要里程碑。LENZ已开始向验光师和眼科医生进行全国范围的样品分发，使专业人士能够为患者提供早期使用的机会。

According to LENZ, consumer shipments through the company’s ePharmacy partner will begin in October 2025, with broad retail pharmacy availability anticipated by mid-Q4.

根据LENZ公司介绍，通过其电子药房合作伙伴向消费者发货将从2025年10月开始，并预计在第四季度中期实现广泛的零售药店供应。

Eef Schimmelpennink, President and CEO of LENZ Therapeutics, commented:

LENZ治疗公司的总裁兼首席执行官Eef Schimmelpennink评论道：

“We are thrilled to introduce VIZZ to the 128 million adults living with blurry near vision in the United States. The team has been preparing for this moment for months and worked tirelessly to enable the availability of product samples and commercial product following our FDA approval. Initial feedback and early brand awareness from the ECP community is extremely positive, and we feel well-positioned for a successful product launch, firmly establishing VIZZ as a category of one for the treatment of presbyopia.”.

“我们非常高兴向美国1.28亿患有近视力模糊的成年人推出VIZZ。团队为这一刻已经准备了数月，并在获得FDA批准后不懈努力，确保产品样品和商业产品的供应。来自眼科护理专业人士社区的初步反馈和早期品牌认知非常积极，我们相信这次产品发布将会取得成功，稳固确立VIZZ作为治疗老花眼的独特类别。”

Mechanism of Action: Pupil-Selective Aceclidine

作用机制：瞳孔选择性乙酰氯定

VIZZ is powered by aceclidine, a pupil-selective miotic that works by stimulating the iris sphincter muscle, resulting in a pinhole effect that enhances depth of focus. Unlike traditional miotics, VIZZ achieves this effect with minimal stimulation of the ciliary muscle, thereby reducing the risk of inducing a myopic shift..

VIZZ由aceclidine驱动，这是一种选择性作用于瞳孔的缩瞳剂，通过刺激虹膜括约肌产生针孔效应，从而增强焦深。与传统缩瞳剂不同，VIZZ在实现这一效果的同时对睫状肌的刺激较小，从而降低了诱发近视漂移的风险。

The treatment leads to the formation of a sub-2-mm pupil, effectively improving near vision without compromising distance clarity.

该治疗可形成小于2毫米的瞳孔，有效改善近视力，同时不损害远视力清晰度。

CLARITY Phase 3 Trial Results

CLARITY 第三阶段试验结果

In the CLARITY Phase 3 clinical trial, VIZZ demonstrated strong efficacy:

在CLARITY第三阶段临床试验中，VIZZ展现了强大的疗效：

• 93% of participants achieved 20/40 or better near vision

• 93%的参与者获得了20/40或更好的近视力

• Improvements were noted within 30 minutes of instillation

• 在滴注后30分钟内观察到改善

• Effects lasted up to 10 hours

• 效果持续长达10小时

This level of improvement enabled participants to read phone screens and fine print without the need for reading glasses, addressing a major unmet need for the estimated 128 million U.S. adults living with presbyopia.

这种程度的改善使参与者能够阅读手机屏幕和小号字体，而无需老花镜，满足了美国大约 1.28 亿患有老视的成年人的重大未满足需求。